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a b s t r a c t
Ebola viruses andMarburg viruses, members of the ﬁlovirus family, cause severe hemorrhagic fever. The ability
of these viruses to potently counteract host innate immune responses is thought to be an important
component of viral pathogenesis. Several mechanisms of ﬁloviral innate immune evasion have been deﬁned
and are reviewed here. These mechanisms include suppression of type I interferon (IFN) production; inhibition
of IFN-signaling and mechanisms that either prevent cell stress responses or allow the virus to replicate in the
face of such responses. A greater understanding of these innate immune evasion mechanisms may suggest
novel therapeutic approaches for these deadly pathogens.
& 2015 Elsevier Inc. All rights reserved.
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Introduction
The ﬁlovirus family includes the Ebola viruses and the Marburg
viruses (Sanchez et al., 2007). The family is divided into the ebolavirus
genus which has ﬁve species, Zaire ebolavirus, Sudan ebolavirus
(SUDV), Bundibugyo ebolavirus (BDBV), Tai Forrest ebolavirus (TAFV)
and Reston ebolavirus (RESTV). The marburgvirus genus consists of a
single species, Marburg marburgvirus (MARV), but is divided into two
clades. These are zoonotic pathogens that likely used bats as reservoir
hosts (Amman et al., 2012; Pourrut et al., 2009; Towner et al., 2009).
Among the various species, Reston virus is unique in that it has not
been associated with human illness. Of the pathogenic members,
ﬁloviruses have been associated with repeated outbreaks of viral
hemorrhagic fever with high fatality rates (Feldmann and Geisbert,
2010). Before 2014, outbreaks in human populations had been
recognized in equatorial regions of Africa or arose due to export of
non-human primates from this region of the continent. However, in
March of 2014 an Ebola virus outbreak was recognized in the West
African country of Guinea (Baize et al., 2014). This outbreak spread to
the neighboring countries of Sierra Leone and Liberia, becoming the
largest ﬁlovirus outbreak on record, having caused, according to World
Health Organization (2015) numbers, 22,092 cases of Ebola virus
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disease and 8810 deaths as of January 21, 2015. Infected individuals
also brought the virus to the United States, the United Kingdom and
Europe, highlighting the global public health importance of these
viruses.
Many aspects of the structure and molecular biology of ﬁloviruses
are well-described (Sanchez et al., 2007). They are ﬁlamentous,
enveloped, negative-sense RNA viruses. The surface of the virus has
a single virus-encoded glycoprotein (GP) that mediates virus attach-
ment and entry. Underlying the viral membrane is a viral matrix
comprised mainly of viral protein 40 (VP40). Within the particle is the
uncapped, single-stranded RNA genome which is coated by the viral
nucleoprotein (NP). Also associated with the encapsidated genomic
RNA are the virus encoded proteins VP35, VP30, VP24 and the large
protein (L). The ﬁloviral genome is approximately 19 kb in length and
has 7 distinct transcriptional units (Fig. 1). Viral genome replication
and transcription, resulting in the production of 50-capped, 30-poly-
adenylated mRNAs encoding viral proteins, are carried out in the cell
cytoplasm by a virus encoded RNA-dependent RNA polymerase
(RDRP) complex comprised of NP, VP35, VP30 and L, the enzymatic
component of the RDRP complex.
The connection between ﬁlovirus disease and immune evasion
mechanisms
The severe disease associated with ﬁloviral infection is character-
ized by systemic virus replication, which results in very high titers in
the blood (Feldmann and Geisbert, 2010). A presumed consequence of
this robust virus replication is the appearance of damaging host
responses. These include excessive cytokine production, release of
tissue factor and other mediators that contribute to a severe disease
featuring liver damage, vascular leakage and bleeding (Feldmann and
Geisbert, 2010). The excessive replication reﬂects an ability of Ebola
and Marburg viruses to very effectively counteract host antiviral
defenses, particularly interferon (IFN) responses, which serve as
critical innate immune responses toward virus infection (Basler and
Amarasinghe, 2009; Bray and Geisbert, 2005). An overview of ﬁloviral
mechanisms of innate immune evasion, including several recent
developments, is provided below.
IFN responses
Type I IFNs are critical components of the innate response to viral
infection (Ivashkiv and Donlin, 2014). These are a family of proteins
encoded by a single IFNβ gene and multiple IFNα genes. The interplay
between the type I IFN response, called IFN-α/β hereafter, and
ﬁloviruses has been studied relatively intensively. When expressed,
IFN-α/β are secreted from producing cells and can signal in an
autocrine or paracrine manner by binding to a heterodimeric receptor,
the IFN-α/β receptor, found on the cell surface. This triggers a JAK–STAT
signaling cascade that upregulates hundreds of genes that cumula-
tively render cells resistant to virus infection and better able to block
virus replication. IFN-α/β are encoded in humans and in mice by a
single IFNβ gene and multiple IFNα genes. IFN-α/β gene expression is
inducible following activation of several different pattern recognition
receptor pathways, including the RIG-I-like receptor (RLR) pathways,
select Toll-like receptor (TLR) pathways and the STING/cGAS pathway
(Brubaker et al., 2015). Most likely, two RIG-I-like receptors, RIG-I and
MDA5, have the most relevance to ﬁloviruses. This reﬂects the facts
that the RLRs reside in the cytoplasm of cells, where ﬁloviruses
replicate, and that they detect and signal in response to RNA products
of virus replication. RIG-I senses RNA molecules with features such as
50 triphosphates and dsRNA features, while MDA5 appears to recog-
nize longer dsRNAs. These are features that characterize or may
characterize the products of ﬁlovirus replication and puriﬁed Ebola
virus genomic RNA has in fact been demonstrated to activate RIG-I.
Filovirus VP35 proteins block IFN-α/β production
One major mechanism by which ﬁloviruses evade innate antiviral
defenses is by blocking the RLR pathways that would otherwise
trigger IFN-α/β production. This mechanism is carried out by the VP35
proteins of both Ebola viruses and Marburg viruses. That Ebola virus
VP35 can block IFN-α/β was ﬁrst suggested by the observation that
VP35 expression could complement the growth of a mutant inﬂuenza
A virus that was unable to counteract the IFN-α/β response (Basler
et al., 2000). VP35 expression also prevented activation of the IFN-β
promoter following infection by Sendai virus, a potent IFN-α/β
inducer, or following transfection of the IFN-inducing mimic of virus,
polyI:C (Basler et al., 2000). VP35 was subsequently demonstrated to
prevent phosphorylation of interferon regulatory factor 3 (IRF-3), a
transcription factor critical for induction of the IFN-β promoter (Basler
et al., 2003). VP35 was also shown to impair RIG-I signaling and this
inhibition correlated with the capacity of VP35 to bind to dsRNA
(Cardenas et al., 2006; Hartman et al., 2004) (Fig. 2). In examining the
mechanisms by which VP35 carries out these immune suppressive
functions, several non-mutually exclusive models are supported by
existing data. Because VP35 could impair activation of the IFN-β
promoter in the presence of over-expressed IKKε or TBK1, the kinases
that phosphorylate and activate IRF-3, the impact of VP35 on these
kinases was assessed. VP35 was demonstrated to interact in co-
immunoprecipitation studies with either IKKε or TBK1 via their more
conserved kinase domains. The interaction of VP35 with the kinases
was sufﬁcient to block kinase interaction with, and phosphorylation
of, either IRF-3 or IRF-7 and, in vitro, resulted in the phosphorylation
of VP35 (Prins et al., 2009). While the functional consequence of VP35
phosphorylation is unclear, the ability of VP35 to prevent kinase
phosphorylation of IRF-3 or IRF-7 would be expected to disrupt
induction of IFN-α/β gene expression. A second inhibitory activity of
VP35 that would act downstream of IKKε and TBK1 was also
described. This mechanism was ﬁrst suggested by yeast two-hybrid
assay results, where use of VP35 as bait identiﬁed Ubc9, the E2
enzyme for SUMOylation, and protein inhibitor of activated STAT
(PIAS1, a SUMO E3 ligase) as interactors. Through this interaction,
VP35 enhanced SUMOylation of IRF-7 and IRF-3, likely contributing to
suppression of IFN-α/β gene transcription (Chang et al., 2009).
As noted above, VP35 is a dsRNA binding protein and point
mutations that disrupt VP35 inhibition of virus or dsRNA-induced
IFN-α/β responses have been described (Cardenas et al., 2006; Leung
et al., 2010a). These mutations do not signiﬁcantly impact VP35
function as part of the Ebola virus RDRP complex, indicating that they
do not promote the misfolding of the protein (Leung et al., 2010a;
Prins et al., 2010). In addition, when IKKε or TBK1 are over-expressed,
the over-expression is sufﬁcient to trigger IFN-β gene transcription.
Expression of VP35 is sufﬁcient to inhibit this activation and VP35
mutants unable to bind to dsRNA were as effective as wild-type VP35
in this assay. These same mutants are severely impaired in blocking
IFN-α/β induction by Sendai virus or transfected dsRNA. Therefore,
NP VP35 VP40 GP/sGP VP30 VP24 L3’ 5’
Fig. 1. Genome organization of ﬁloviruses. The names of genes, designated according to proteins encoded by each, are indicated. NP, nucleoprotein; VP35, viral protein 35;
VP40, viral protein 40; GP/sGP, glycoprotein, soluble glycoprotein; VP30, viral protein 30; VP24, viral protein 24; L, Large protein (the viral polymerase). Note that Marburg
virus encodes GP but not sGP. The spacing between genes is variable and is not drawn to scale.
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there is a dsRNA binding-dependent mechanism that makes the major
contribution to suppression of RIG-I-dependent IFN-α/β responses.
Two dsRNA-dependent mechanisms of VP35 function have also
been proposed: 1) the sequestration of RLR-activating RNAs and 2)
the interaction of VP35 with cellular protein PACT, which interacts
with RIG-I and facilitates its activation by dsRNA (Kimberlin et al.,
2010; Leung et al., 2010a; Luthra et al., 2013; Prins et al., 2010). VP35
suppresses gene silencing by small interfering RNAs (Fabozzi et al.,
2011; Haasnoot et al., 2007; Zhu et al., 2012). The biological
signiﬁcance of this observation is unclear, but it led investigators to
examine VP35 interactions with the RNA silencing machinery
(Fabozzi et al., 2011); this identiﬁed an interaction between VP35
and PACT. PACT has multiple functions, including modulation of Dicer
activity and protein activation of the IFN-induced antiviral kinase, PKR
(Lee et al., 2013a; Patel and Sen, 1998). However, PACT can also
interact with RIG-I and promote its activation (Kok et al., 2011).
Therefore, studies were performed to evaluate the consequences of
VP35–PACT interaction for IFN-α/β induction via RIG-I (Luthra et al.,
2013). The data demonstrated that VP35 interacts with PACT in such a
manner that PACT is unable to interact with RIG-I. This impairs PACT
activation of RIG-I and induction of IFN-α/β gene expression by either
Sendai virus or transfected dsRNAs. Cells lacking PACT were impaired
for induction of IFN-β promoter activation and therefore, introduction
of VP35 into these cells had little impact. However, adding back PACT
by transfection restored the IFN-α/β response and under these
circumstances VP35 suppressed the response. Point mutations in
VP35 that disrupted dsRNA binding abrogated VP35–PACT interaction
and VP35 became unable to disrupt PACT–RIG-I interaction. This
resulted in a loss of VP35 inhibition of PACT-facilitated activation of
RIG-I. Given that PACT is also a dsRNA-binding protein, a dsRNA
bridge between VP35 and PACT seemed plausible. However, in vitro
binding studies using puriﬁed components in the absence or presence
of RNAses suggest a direct protein–protein interaction. This suggests
that the same VP35 amino acid residues that mediate interactionwith
dsRNA also contribute to direct interaction with PACT (Luthra et al.,
2013). As discussed below, some of the basic residues in VP35 that
directly contact the dsRNA phosphodiester backbone in VP35–dsRNA
X-ray crystal structures also make VP35–VP35 contacts in the
structure (Leung et al., 2010b). Therefore, it is plausible that these
same residues can also participate in protein–protein interactions
with a host factor.
The relevance of PACT for EBOV infection was demonstrated with
PACT-over-expression and PACT knockdown studies (Luthra et al.,
2013). PACT over-expression enhanced IFN-α/β responses when cells
were infected with either wild-type or mutant VP35 Ebola viruses,
presumably because excess PACT can overcome the inhibitory effects
of even wild-type VP35. Knockdown of PACT could reverse the IFN-α/β
response in cells infected with a VP35 mutant virus. These observa-
tions provide compelling evidence that interaction with PACT con-
tributes to the immune suppression caused by VP35. However, these
results do not rule out other mechanisms of inhibition, including the
sequestration of RLR-activating dsRNAs (Bale et al., 2012, 2013; Leung
et al., 2010b).
The interaction of PACT with VP35 has a second functional
consequence. As noted above, VP35 plays a critical role in ﬁloviral
genome replication and mRNA synthesis, because it serves as a co-
factor for the enzymatic subunit of the viral RNA-dependent RNA
polymerase, the large protein (L). Through interaction with L and the
viral nucleoprotein (NP), VP35 brings L to the NP-encapsidated
template RNA. The ﬁloviral RNA polymerase complex can be recon-
stituted by expression of its protein components and its function can
be assayed by co-expression of a model viral genomic RNA encoding a
reporter gene (Muhlberger et al., 1998, 1999). When PACT is co-
expressed with this system, it impairs viral RNA synthesis (Luthra
et al., 2013). This impairment requires interaction with VP35, because
the RNA synthesis system is affected by PACT when wild-type VP35 is
used, but not when the PACT binding-defective mutants of VP35 are
used in the system. Co-immunoprecipitation experiments indicated
that PACT could impair VP35 interaction with L, providing a likely
explanation for the inhibition. Together, these observations identify a
unique impact of a host innate immune signaling protein on the
function of a negative-sense RNA virus polymerase. It is intriguing to
hypothesize that the ﬁlovirus RDRP complex may respond to the
innate immune status of the host cell, as this would allow the virus to
modulate production of RLR activating RNAs. However, it is unclear
whether the level of PACT or PACT availability changes in response to
virus infection.
In addition to suppressing IFN-α/β production, VP35 inhibits the
activation of the IFN-induced, dsRNA-activated kinase PKR, a well-
characterized kinase with antiviral activity (Feng et al., 2007;
Schumann et al., 2009). Although activated by dsRNA or by PACT,
some VP35 point mutants defective for dsRNA binding still inhibit
PKR. Therefore, the as yet to be deﬁned mechanism of inhibition
appears to be dsRNA-binding independent. It is suggestive that PACT
is a PKR activator, but a direct connection between VP35–PACT
interaction and VP35–PKR inhibition has not been demonstrated.
How VP35 inhibition of PKR inﬂuences EBOV replication is also,
as yet, undeﬁned; however, there is some evidence that this function
can impact virus growth in vitro. Phosphorylation of PKR and
dsRNA
RIG-I/
MDA5
PACT
TRAF3
TANK
IKKε  TBK-1
IRF-
3/7 IRF-
3/7
IRF-
3/7
IRF-
3/7
IRF-
3/7
IFNβ
Nucleus
IFNβ Promoter
MAVS
Mitochondria
eVP35
eVP35
P P
P
P P
P P
Cytoplasm
Ebolavirus/
Marburgvirus
VP35
Fig. 2. Filovirus VP35 proteins block RIG-I signaling at more than one step. Filoviruses
enter the host cell via micropinocytosis and escape the endosome (depicted as a
circle containing a virus). The viral genome escapes into the cytoplasm where
replication reactions occur. Products of viral RNA synthesis, which may include
RNAs with dsRNA features (depicted) and RNA with 50-triphosphates are recog-
nized by RIG-I or MDA5. This, aided by host protein PACT, activates RIG-I or MDA5
signaling and stimulates a signaling pathway that leads to activation of kinases
IKKε and TBK1. These phosphorylate interferon regulatory factors 3 or 7 (IRF3/7)
which then dimerize, move to the nucleus and contribute to IFN-α/β gene
expression. VP35 can bind to dsRNA, can block PACT activation of RIG-I and can
prevent IKKε and TBK1 phosphorylation of IRF-3 and IRF-7.
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phosphorylation of the PKR substrate eIF-2α are not detectable in
infected 293 cells, suggesting effective suppression of PKR by the
virus. Further, reactivation of lytic Ebola virus replication could be
restored in persistently infected cells by modulating the status of
eIF-2α phosphorylation (Schumann et al., 2009; Strong et al., 2008).
VP35 promotes suppression of dendritic cell function
Another consequence of VP35 innate immune suppression is
disruption of dendritic cell (DC) maturation. DCs serve as a critical
link between innate and adaptive immunity; upon encountering
pathogens. DCs are important targets of Ebola and Marburg viruses
in vivo (Geisbert et al., 2003); both viruses also productively replicate
in DCs and potently suppress maturation and function (Bosio et al.,
2003; Lubaki et al., 2013; Mahanty et al., 2003). Upon infection by
Ebola virus, DCs undergo aberrant maturation where production of
IFN-α/β and inﬂammatory cytokines and upregulation of costimula-
tory markers are impaired; the infected DCs also fail to activate naïve
T cells. However, infection of cells with recombinant Ebola viruses
expressing mutant VP35s results in DC activation, suggesting a
critical role for VP35 in DC suppression (Lubaki et al., 2013). Further
demonstrating this role for VP35 in DCs, VP35 expression recapitu-
lates many of the suppressive effects seenwith EBOV infection (Bosio
et al., 2003; Jin et al., 2009; Yen et al., 2014). The inhibitory role of
VP35 is related to its ability to antagonize the function of RLRs, IKKε
and TBK1 (Yen et al., 2014). This is evidenced by the ability of VP35 to
impair several aspects of DC maturation and function induced by RLR
agonists. Functions affected include IFN-α/β and cytokine production,
upregulation of costimulatory markers, and T cell activation. When
Toll-like receptors were activated, VP35 could impair IFN-α/β produc-
tion induced by TLR4 agonist LPS; however, VP35 did not impair
cytokine production induced by LPS or TLR2 agonist zymosan (Leung
et al., 2011; Yen et al., 2014). This suggests that VP35 does not
globally impair TLR signaling, a conclusion reached by other studies
as well (Leung et al., 2011). Rather, the speciﬁc impairment of TLR-
induced IFN-α/β response may reﬂect the inhibition of IKKε and TBK1.
Although Ebola virus infection does trigger speciﬁc T cell responses
in vivo, the suppression of RLR signaling and resulting block in DC
maturation may slow T cell responses and contribute to the failure of
adaptive immune responses. That TLR signaling can at least partially
bypass the effects of VP35 suggests that it may be possible to
stimulate maturation of ﬁlovirus-infected DCs.
Structural basis for VP35 function
Because the dsRNA binding activity of VP35 correlates with its
IFN-antagonist function, the basis by which VP35 binds to dsRNA is
of signiﬁcant interest. Biophysical and structural approaches have
therefore been applied to this problem. Ebola virus VP35 possesses
a carboxy-terminal domain, comprised of residues 220-340, that is
sufﬁcient to bind dsRNA (Bale et al., 2013; Leung et al., 2010a). This
same domain is sufﬁcient for suppression of IFN production,
although inclusion of the amino-terminal half of VP35, which
provides an oligomerization activity, enhances IFN inhibition
(Leung et al., 2010a; Reid et al., 2005). Because of its role in IFN-
antagonist function, the carboxy-terminal domain has been called
the “interferon inhibitory domain” or IID. The X-ray crystal struc-
ture of the IID has been solved for Zaire Ebola virus, Reston virus
and Marburg virus. These are very structurally similar, despite
limited sequence homology (42.9% percent amino acid identity
between Ebola and Marburg virus IIDs). The IID has an alpha-helical
subdomain, a beta-sheet subdomain and two basic patches. The
“central basic patch” (CBP) contributes to VP35 suppression of RLR
signaling, whereas the “ﬁrst basic patch” is important for VP35
function in the RDRP complex (Leung et al., 2010b).
Despite their similarities, some differences between the Ebola and
Marburg VP35 IIDs have been described. For example, the minimum
length of dsRNA bound by Ebola virus IID (8 bp) is shorter than that
for Marburg virus IID (12 bp), and Ebola virus IID binds dsRNAs with
higher afﬁnity than does Marburg virus IID (Bale et al., 2012;
Ramanan et al., 2012). There are also differences in how each IID
recognizes RNA. Ebola virus IID recognizes the dsRNA phosphodiester
backbone of the RNA but also engages the blunt ends of the dsRNA. In
contrast, Marburg virus IID lacks the “endcapping” function of Ebola
virus; this could conceivably affect the ability of Ebola versusMarburg
virus VP35s to prevent recognition of 50-triphosphate-containing
dsRNA by RIG-I (Ramanan et al., 2012).
VP35 IFN-antagonist function and virulence
Studies with recombinant ﬁloviruses bearing mutations in VP35
demonstrate that VP35 innate immune suppressing functions are
important for virus propagation and virulence (Prins et al., 2010).
Ebola and Marburg virus mutants, where central basic patch residues
have been mutated to alanine, have been recovered. These viruses
grow well in cell culture, provided Vero cells are used, because these
cells are defective for IFNα⧸β production. In cells that have an intact
IFN-α/β response, the VP35 mutant viruses elicit strong antiviral
responses and exhibit impaired replication, features absent following
infection with wild-type VP35 viruses. In mice, a wild-type VP35 virus
grewwell in infected animals, but a VP35mutant virus grew poorly. In
guinea pigs, a wild-type VP35 control was lethal, but a VP35 mutant
caused no illness or death and even protected animals from challenge
with wild-type virus 17 days after the initial inoculation with the
mutant. Therefore, VP35 IFN-antagonist function is critical for viru-
lence and might serve as a target for antivirals. Remaining to be
clariﬁed is the contribution of the various VP35 inhibitory activities.
Mutant viruses with speciﬁc defects in PACT interaction, IKKε/TBK1
interaction or PKR inhibition, for example, would help to answer such
questions.
Ebola virus VP24 and Marburg virus VP40 proteins block IFN
signaling
Filovirus infected cells fail to respond to exogenously added IFN-α/
β or IFNγ (Harcourt et al., 1999; Kash et al., 2006). This may contribute
to the failure of IFNs as therapeutics and the facilitation of virus
spread in vivo. Ebola and Marburg viruses have each been demon-
strated to impair the Jak–STAT signaling normally triggered by IFNs,
however, the mechanisms differ (Fig. 3). For Ebola viruses, the VP24
protein is sufﬁcient to block IFN signaling (Reid et al., 2006). When
cells are infected with Ebola virus or when eVP24 is expressed, IFN
addition results in STAT1 tyrosine phosphorylation, as normally
occurs. However, whereas tyrosine phosphorylated STAT1 (PY-STAT1)
normally localizes rapidly to the nucleus following IFN addition, this
fails to happen in Ebola virus-infected or VP24-expressing cells. This
effect correlates with the interaction of eVP24 with select karyo-
pherin alpha (KPNA: also known as importin alpha) proteins (Reid
et al., 2006, 2007). The KPNA proteins are a family of nuclear import
factors that in complex with importin beta shuttle cargo through the
nuclear pore (McBride and Reich, 2003). The KPNA family is divided
into subfamilies. eVP24 interacts speciﬁcally with members of one
subfamily, the NPI-1 KPNAs (KPNA1, KPNA5 and KPNA6), and not
with other KNPAs. PY-STAT1 has the same KPNA binding proﬁle, and
interaction with these KPNAs allows the IFN-induced nuclear accu-
mulation of PY-STAT1 necessary for IFN induction of gene expression
(Reid et al., 2006, 2007).
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Co-immunoprecipitation and mapping experiments suggested that
eVP24 and PY-STAT1 share a common binding site on the KPNAs and
that eVP24 might compete with PY-STAT1 for KPNA to block IFN
responses (Reid et al., 2006, 2007). Biochemistry and structural biology
have conﬁrmed this proposed competition model. The X-ray crystal
structure of eVP24 revealed a pyramid-shaped protein in which
multiple α-helices sit on a β-sheet “pedestal” (Edwards et al., 2014;
Zhang et al., 2012). To determine how this structure interacts with
KPNAs, a minimal region of KPNA5 necessary to bind to eVP24 was
deﬁned, and a co-crystal structure of this domain and eVP24 was
solved (Xu et al., 2014).
KPNA proteins can be divided into distinct domains: 1) an N-
terminal domain that binds importin beta is important, as importin
beta mediates transport of the cargo-containing complex through the
nuclear pore; 2) 10 armadillo (ARM) repeats mediate interactions
with nuclear localization signals (NLSs); and 3) a carboxy-terminal
domain. Proteins possessing classical nuclear localization signals
(cNLSs), mono- or bi-partite stretches of basic residues, bind to the
central ARM repeats; however, PY-STAT1 possesses a non-classical
NLS (ncNLS) and binds to a region that includes ARMS 8-10. The
eVP24–KPNA5 structure identiﬁed interactions between eVP24 and
each of ARM repeats 8, 9, and 10 (Edwards et al., 2014; Xu et al.,
2014). Mutations designed based on the structure and accompanying
binding studies demonstrated that interaction of eVP24 with this
region of KPNA5 is needed for inhibition of PY-STAT1 nuclear
accumulation. Consistent with a competition model, the same region
of KPNA5 is critical for PY-STAT1, and wild-type eVP24 can disrupt
PY-STAT1 binding to KPNA5. However, eVP24 mutants that do not
bind KPNA5 fail to compete for binding by PY-STAT1. The interaction
of eVP24 with KPNA5 does not appear to affect the cNLS binding site
on KPNA nor does it affect KPNA5 interaction with a monopartite
cNLS cargo. Therefore eVP24 may be fairly selective in how it impacts
nuclear trafﬁcking. This selectivity might facilitate survival of the
infected cell. It remains possible, however, that bipartite cNLSs and
other ncNLS cargo will be affected by eVP24 (Shabman et al., 2011;
Xu et al., 2014). Additional characterization of nuclear trafﬁcking will
therefore be needed to further clarify the full impact of Ebola virus-
infection or eVP24-expression on the host cell.
Instead of blocking PY-STAT1 nuclear import, Marburg virus
infection prevents the tyrosine phosphorylation events that typi-
cally characterize IFN signaling (Valmas et al., 2010). Expression of
the Marburg virus VP40 protein (mVP40), but not the Marburg virus
VP24 protein (mVP24), could reproduce this effect. In the case of
IFN-α/β, tyrosine phosphorylation was absent for the receptor
associated kinases, Jak1, Tyk2, STAT1 and STAT2 (Valmas et al.,
2010). The impact on IFNγ signaling was the same; Jak and STAT
tyrosine phosphorylation was disrupted (Rodig et al., 1998;
Rodriguez et al., 2004). Jak1 knockout cells also have a phenotype
for the IL-6 signaling pathway where IL-6-induced STAT1 phosphor-
ylation becomes undetectable and STAT3 phosphorylation is
reduced (Rodig et al., 1998). Expression of mVP40 reproduced this
phenotype as well (Valmas et al., 2010). Indications are that mVP40
speciﬁcally targets Jak1 function: while over-expressing Jak1 results
in phosphorylation of JAK1, STAT1 and STAT2, expression of mVP40
prevents this. However, in a similar experiment in which Jak family
kinase Tyk2 is over-expressed, mVP40 had little to no impact on
Tyk2, STAT1 or STAT2 phosphorylation.
How mVP40 inhibits Jak1 remains to be deﬁned. However,
evidence suggests that the function is relevant to virus host range
and pathogenesis. Marburg virus is not lethal in immune competent
mice, but serial passage in mice adapts the virus such that it
becomes deadly following intraperitoneal inoculation (Lofts et al.,
2011; Warﬁeld et al., 2007). Whereas the mVP40 from a parental
virus effectively blocks IFN signaling in human cell lines, no
inhibition was detected in mouse cell lines (Valmas and Basler,
2011). However, following mouse-adaptation of two different Mar-
burg virus strains, Ci67 and Ravn, mVP40 had acquired the ability to
inhibit IFN signaling in mouse cells (Feagins and Basler, In press;
Valmas and Basler, 2011). Mapping studies implicated different
amino acid changes as sufﬁcient to allow each mVP40 to block IFN
signaling in mouse cells, suggesting a signiﬁcant genetic plasticity
for mVP40 IFN-antagonist function. Interestingly, mVP40 is the viral
matrix protein and it directs budding of virus particles at the
plasma membrane. While the parental mVP40s efﬁciently bud from
both human and mouse cell lines, the mouse-adapted mVP40s
exhibit reduced budding from human cells, but not from mouse
cells. The precise mechanism by which mouse-adaptation impacts
budding is not yet fully elucidated, but an association was made to
the function of the IFN-inducible antiviral protein tetherin (Feagins
and Basler, 2014). In assays performed in Hepa1.6 cells, a mouse-
derived cell line, human, but not mouse, tetherin could impede
budding of the mouse-adapted mVP40, but not the parental mVP40.
These ﬁndings suggest that there are functional costs associated
with adaptation of MARV to new hosts and they also provide an
intriguing link between host range, innate immune evasion and
virus assembly functions.
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Fig. 3. Filoviruses block IFN signaling. Addition of IFNα or IFNβ to cells triggers a Jak–
STAT signaling pathway which leads to tyrosine phosphorylation of STAT1 and
STAT2. These dimerize and enter the nucleus through interactions with karyo-
pherin alpha (KPNA) proteins. In the nucleus, a STAT1–STAT2–IRF9 complex
activates IFN-stimulated response element (ISRE)-containing promoters. This leads
to the upregulation of IFN stimulated genes such as MHC Class 1 and PKR. Ebola
virus VP24 (eVP24) blocks interaction of phospho-STAT1 with KPNA proteins,
preventing STAT1–STAT2 nuclear import. Marburg virus VP40 (mVP40) inhibits
Jak1 function.
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Marburg virus VP24 interacts with Keap1 and modulates
antioxidant responses
Although Marburg virus VP24 (mVP24) does not interact with
KPNAs or block IFN signaling, it does modulate host responses in
novel ways. A proteomics study and a yeast two hybrid screen each
identiﬁed as an mVP24 interaction partner the cellular protein
kelch-like ech-associated protein 1 (Keap1) (Page et al., 2014;
Pichlmair et al., 2012). Keap1 is best characterized for its role in
directing the Cul3 ubiquitin ligase-mediated ubiquitination and
degradation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2)
(Copple et al., 2008; Taguchi et al., 2011). Nrf2 is a transcription
factor that associates with small Maf proteins and binds to promo-
ters possessing antioxidant response element (ARE) sequences.
Under normal circumstances, Nrf2 is targeted for degradation by
Keap1. However, under conditions of stress, such as oxidative stress,
the Keap1–Nrf2 interaction is destabilized. This reduces Nrf2 degra-
dation, allows Nrf2 levels to increase and results in the expression of
ARE genes, the products of which confer a cytoprotective state that
allows cells to recover from stress (Copple, 2012). There have been
increasing associations between the antioxidant response and virus
infection. For example, Nrf2 has been shown to be activated by
inﬂuenza virus and respiratory syncytial virus infection, where it
may exert antiviral effects (Cho et al., 2009; Kesic et al., 2011).
However, stimulation of cytoprotective antioxidant responses may
also promote survival of virus-infected cells and regulate expression
of the immunoproteasome, thereby altering antigen presentation
(Burdette et al., 2010; Ivanov et al., 2011; Lee et al., 2013b; Schaedler
et al., 2010). What distinguished interaction of mVP24 with Keap1
from other examples of viral engagement of the antioxidant
response is the direct engagement of a viral protein with a key
component of this pathway.
Cell based and in vitro studies conﬁrmed the interaction of VP24
with the six-bladed beta sheet propeller Kelch domain of Keap1, the
same domain of Keap1 that interacts with Nrf2 (Edwards et al., 2014;
Page et al., 2014). On the mVP24 side, interaction requires an acid
motif that is present within a loop dubbed the K-loop (Edwards et al.,
2014). This motif included the amino acid residues “GE,” similar with
additional acidic residues nearby, but upstream. This is similar to
Keap1 interacting motifs found on other proteins including Nrf2. This
motif sits at the end of extended beta-strands that project from the
body of mVP24 and constitute the major structural difference between
eVP24 and mVP24 (Zhang et al., 2014). Sticking out from the rest of
mVP24 would allow insertion of the acidic motif into the Kelch β-
propeller. That this structural motif is critical for the interaction was
supported by transfer of the mVP24 acidic motif onto eVP24, which
allowed eVP24 to bind Keap1, and by mutation studies where
mutation of the K-loop sequence disrupted mVP24–Keap1 binding
(Edwards et al., 2014).
Functionally, disruption of Keap1–Nrf2 interaction should activate
ARE gene expression. mVP24 expression can interrupt binding of
Keap1 to Nrf2 and turn on ARE gene expression as well (Edwards et
al., 2014). This correlates with binding to Keap1, as eVP24 or mVP24
mutants unable to interact with Keap1 did not activate ARE gene
expression. However, the eVP24–mVP24 chimera that binds to Keap1
also activates ARE genes. Expression of mVP24 could also render cells
resistant to killing by menadione, a chemical that causes oxidative
damage. Relevance to Marburg virus infection was suggested by a
comparison of host gene expression following infection of THP-1 cells
with Ebola virus or Marburg virus. Whereas Ebola virus did not cause
an upregulation of ARE genes, Marburg virus infection did. One
hypothesis as to why Marburg viruses evolved this interaction is that
the upregulation of cytoprotective antioxidant responses may prolong
the life of infected cells. In fact, Keap1 has been reported to interact
with and regulate additional pathways that also inﬂuence cell survival
including phosphoglycerate mutase family member 5 (pgam5), the
kinase IKKβ, and autophagy factor p62 (Kim et al., 2010; Komatsu
et al., 2010; Lau et al., 2010; Lee et al., 2009; Lo and Hannink, 2006).
Nonetheless, the deﬁnitive consequences of mVP24–Keap1 interaction
for Marburg virus remain to be deﬁned. It is intriguing that heme
oxygenase 1 (HO-1), one well-characterized ARE gene, inhibits EBOV
replication (Hill-Batorski et al., 2013). Therefore, in addition to
differences in terms of whether or not Ebola and Marburg viruses
activate the antioxidant response, there may be differences in the
consequences of such activation as well.
Upstream open reading frames in ﬁloviral mRNAs regulate viral
protein synthesis in response to cell stress
A major mechanism of stress-induced translation inhibition is the
phosphorylation of translation initiation factor eIF-2α, a target of
several stress-activated kinases including PKR, a long recognized IFN-
α/β induced antiviral protein (Gale and Katze, 1998). However,
translation of a number of cellular mRNAs is upregulated in response
to cell stress that triggers eIF-2α phosphorylation. One strategy
employed by several cellular mRNAs (including those encoding the
ATF4, CHOP and GCN2 proteins) to overcome translation inhibition
due to eIF-2α phosphorylation involves upstream AUGs (uAUGs) and
upstream open reading frames (uORFs) located within the 50-
untranslated regions (UTRs) (Hinnebusch, 1997; Palam et al., 2011;
Vattem and Wek, 2004; Wek et al., 2006). Under normal conditions,
a complex consisting of eIF2-GTP-Met-tRNA binds to the 40S subunit
forming the 43S preinitiation complex (Wong et al., 2014). The 43S
subunit scans the mRNA to a start codon where translation initiation
occurs. When eIF2αP is increased, eIF2-GTP levels decrease, and
translation initiation is less efﬁcient. In the presence of eIF2αP,
ribosome initiation at uAUGs is reduced, allowing scanning and
initiation at the downstream primary ORF (pORF; referred to as the
leaky scanning model).
Notably, the 50-UTRs of several EBOV mRNAs (for VP35, VP30,
VP24 and L) possess uAUGs and uORFs prior to the pORF that
encodes the viral protein. When examined in transfection assays in
which viral 50UTRs were placed upstream of reporter genes, the L
50UTR was notable because it suppressed translation of the reporter
by about 10-fold, and this suppression required the presence of the
uAUG within the 50UTR. The L 50UTR resembles the CHOP mRNA,
where a single uORF modulates translation in response to cell stress
(Geisbert et al., 2014; Palam et al., 2011). Like the situation for CHOP,
under conditions of cell stress where eIF2αP levels are increased,
the EBOV L uORF promotes enhanced expression of the pORF (L)
(Shabman et al., 2013). Speciﬁcally, when eIF-2α phosphorylation
was induced by thapsigargin, the L 50UTRwas resistant to translation
inhibition and expression increased modestly. Further, when the L
uAUG was mutated in the context of a recombinant Ebola virus,
virus replication was attenuated and the mutant virus was more
sensitive to inhibition by thapsigargin than was wild-type virus.
These data point to the L uAUG as a mechanism by which the virus
can sustain the appropriate level of its polymerase even in the face
of an innate immune response.
Similar to the L uORF, uORFs in VP35, VP30 and VP24 may also
serve to sustain viral protein expression in the face of cell stress, such
as stresses which are due to virus activation of either PKR or ER stress
(which also induces eIF2αP). Given the role of VP35 and VP24 in
suppressing innate antiviral responses, it may be that their uAUGs help
preserve expression of these proteins under conditions where innate
immune responses have activated the PKR pathway. It is also notable
that VP35 and VP30 are, along with L, essential for viral RNA synthesis
(Muhlberger et al., 1998, 1999). Perhaps, induction of eIF2αP would
result in upregulation of VP35, VP30 and L expression to sustain
replication, while upregulation of VP35 and VP24 would also enhance
viral counter-defenses against innate immunity.
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GP inhibition of tetherin
The host protein tetherin, also known at BST2, is an IFN-induced
protein that can inhibit budding and release of enveloped viruses
(Neil, 2013). It also plays a role in stimulating immune responses by
activating NF-kB signaling (Cocka and Bates, 2012; Tokarev et al.,
2013). Tetherin expression was demonstrated to antagonize budding
of the Ebola virus VP40 protein in transfection studies (Jouvenet et al.,
2009). However, tetherin did not inhibit Ebola virus replication
(Radoshitzky et al., 2010). Ebola virus GP was found to account for
this apparent discrepancy in that expression of GP could rescue VP40
budding in the presence of tetherin (Kaletsky et al., 2009). Marburg
virus GP also counteracts tetherin (Kaletsky et al., 2009). Precisely
how GP exerts its anti-tetherin effects remains ambiguous; it does not
seem to affect tetherin stability, remove tetherin from the plasma
membrane or disrupt tetherin localization to lipid rafts (Lopez et al.,
2012, 2010). In addition to these mechanistic questions, it will be of
interest to deﬁne the contribution of tetherin antagonism to ﬁloviral
pathogenesis. The Marburg virus VP40 variants noted above, which
exhibit enhanced sensitivity to restriction by tetherin, may be useful
in this regard (Feagins and Basler, 2014). However, identiﬁcation of GP
mutants that lose the ability to block tetherin function may be needed
to fully address this question.
Future directions
As evidenced by the information summarized above, much is now
known about ﬁloviral innate immune evasion. Nonetheless, much
remains to be learned. For example, the fact that VP35 is part of the
viral RNA replication machinery and that its function as part of the
viral RDRP complex is modulated by interaction with PACT suggests
connections between viral innate immune evasion and function and
viral replication. Similarly, the fact that uORFs modulate L expression
in response to cell stress provides another link between immune
escape and viral RNA synthesis. That an RNA virus might be able to
adjust its genome replication rate according to the innate immune
status of the host cell would make sense, as viral RNA synthesis
reactions create the RNAs that activate innate immune responses.
Therefore, further investigation into how these functions are inte-
grated is warranted. Because ﬁloviruses are zoonotic pathogens that
presumably have adapted to bats, it will be important to determine
how the innate immune evasion functions that work so completely in
humans and non-human primates act in bats and whether the lower
virulence of ﬁloviruses in their reservoir hosts is due to less potent
innate immune suppression. Animal studies demonstrate the critical
role played by VP35 IFN-antagonist function in terms of causing
disease. Yet, it remains unclear to what extent the ﬁloviral innate
immune evasion functions shape the adaptive immune response and
to what extent factors other than VP35 contribute. Finally, with
detailed mechanistic insights now available, it will be important to
use this information to inform novel therapeutic approaches for these
terrible pathogens.
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